stoxline Quote Chart Rank Option Currency Glossary
Affimed N.V. (AFMD)
0.3998  -0.029 (-6.76%)    12-07 16:00
Open: 0.4426
High: 0.4426
Volume: 1,270,942
Pre. Close: 0.4288
Low: 0.3821
Market Cap: 60(M)
Technical analysis
2023-12-07 4:18:50 PM
Short term     
Mid term     
Targets 6-month :  0.53 1-year :  0.64
Resists First :  0.45 Second :  0.55
Pivot price 0.45
Supports First :  0.31 Second :  0.25
MAs MA(5) :  0.43 MA(20) :  0.42
MA(100) :  0.47 MA(250) :  0.73
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  40 D(3) :  50.4
RSI RSI(14): 45.3
52-week High :  2.07 Low :  0.22
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AFMD ] has closed above bottom band by 17.2%. Bollinger Bands are 43.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.47 - 0.47 0.47 - 0.48
Low: 0.41 - 0.41 0.41 - 0.41
Close: 0.42 - 0.43 0.43 - 0.43
Company Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Headline News

Mon, 04 Dec 2023
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24 - Yahoo Finance

Thu, 30 Nov 2023
Affimed stock falls as finance and science heads exit - Seeking Alpha

Mon, 20 Nov 2023
Affimed N.V. (NASDAQ:AFMD) Q3 2023 Earnings Call Transcript - Yahoo Finance

Tue, 14 Nov 2023
Affimed N.V.: Q3 Earnings Snapshot - Quartz

Wed, 25 Oct 2023
Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround - Yahoo Finance

Wed, 04 Oct 2023
Affimed Announces Listing Transfer to Nasdaq Capital Markets - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 149 (M)
Held by Insiders 1.2629e+008 (%)
Held by Institutions 4.6 (%)
Shares Short 1,620 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.139e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 274.1 %
Return on Equity (ttm) -40.2 %
Qtrly Rev. Growth 2.102e+007 %
Gross Profit (p.s.) -42.03
Sales Per Share -44.72
EBITDA (p.s.) 2.07101e+007
Qtrly Earnings Growth -0.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -116 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 1.62
Stock Dividends
Dividend 0
Forward Dividend 1.64e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android